BioWorld

Dec. 1, 2005

View Archived Issues

InSite's Pink Eye Treatment Proves Positive In Phase III

Read More

PIramed In $230M Preclinical Cancer Deal With Genentech

Read More

VC Syndication Key For Young European Biotechnology Firms

Read More

Other News To Note

Read More

BioCryst Out-Licenses BCX-4208 To Roche In Potential $560M Deal

The holiday season is coming early to BioCryst Pharmaceuticals Inc., which could earn more than half a billion dollars per terms of a just-announced licensing deal with F. Hoffmann-La Roche Ltd. (BioWorld Today) Read More